A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study

Practice for General Medicine, Berlin, Germany.
Obesity (Impact Factor: 3.73). 03/2013; 21(1):58-64. DOI: 10.1002/oby.20244
Source: PubMed


A proprietary natural fiber complex (Litramine IQP G-002AS) derived from Opuntia ficus-indica, and standardized on lipophilic activity, was previously shown in preclinical and human studies to reduce dietary fat absorption through gastrointestinal (GI) fat binding. Here, we investigated the efficacy and safety of IQP G-002AS in body weight reduction.
One hundred twenty-five overweight and obese adults participated in the study. Subjects were advised on physical activity, and received nutritional counseling, including hypocaloric diet plans (30% energy from fat and 500 kcal deficit/day). After a 2-week placebo run-in phase, subjects were randomized to receive either 3 g/day of IQP G-002AS (IQ) or a placebo. The primary endpoint was change in body weight from baseline; secondary endpoints included additional obesity measures and safety parameters.
One hundred twenty-three subjects completed the 12-week treatment phase (intention-to-treat (ITT) population: 30 male and 93 female; mean BMI: 29.6 ± 2.8 kg/m(2) and age: 45.4 ± 11.3 years). The mean body weight change from baseline was 3.8 ± 1.8 kg in IQ vs. 1.4 ± 2.6 kg in placebo (P < 0.001). More IQ subjects lost at least 5% of their initial body weight compared to placebo (P = 0.027). Compared with placebo, IQ also showed significantly greater reduction in BMI, body fat composition, and waist circumference. IQ was well tolerated with no adverse reactions reported.
These results suggest that the natural fiber complex Litramine IQP G-002AS is effective in promoting weight loss.

Download full-text


Available from: Kai-Zhia Lau, Oct 09, 2014
  • Source
    • "P = 0.280) Maki KC, et al., 2007 ID Bell LP, et al., 1990 Schwab U, et al., 2006 Subtotal (I-squared = 32.0%, P = 0.172) High (more than 10 g) Birketvedt GS, et al., 2000 Wood RJ, et al., 2007 Grube B, et al., 2013 Subtotal (I-squared = 56.9%, P = 0.041) Lehtimaki T, et al., 2005 (E4 non-carrier) Kristensen M, et al., 2011 Medium (4–10 g) de Bock M, et al., 2012 Low (up to 3 g) "
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine the effect of different types of dietary fibre on SBP and DBP. A systematic review of the literature and a meta-analysis of randomized controlled trials using random-effects models. Eligibility criteria for studies included randomized controlled trials of at least 6 weeks duration, testing a fibre isolate or fibre-rich diet against a control or placebo published between 1 January 1990 and 1 December 2013. Twenty-eight trials met the inclusion criteria and reported fibre intake and SBP and/or DBP. Eighteen trials were included in a meta-analysis. Studies were categorized into 1 of 12 fibre-type categories. The pooled estimates for all fibre types were -0.9 mmHg [95% confidence interval (CI) -2.5 to 0.6 mmHg] and -0.7 mmHg (95% CI -1.9 to 0.5 mmHg) for SBP and DBP, respectively. The median difference in total fibre was 6 g. Analyses of specific fibre types concluded that diets rich in beta-glucans reduce SBP by 2.9 mmHg (95% CI 0.9 to 4.9 mmHg) and DBP by 1.5 mmHg (95% CI 0.2 to 2.7 mmHg) for a median difference in beta-glucans of 4 g. Heterogeneity for individual fibre types was generally low. Higher consumption of beta-glucan fibre is associated with lower SBP and DBP. The results of this review are consistent with recommendations to increase consumption of foods rich in dietary fibre, but some additional emphasis on sources of beta-glucans, such as oats and barley, may be warranted.
    Journal of Hypertension 02/2015; 33(5). DOI:10.1097/HJH.0000000000000515 · 4.72 Impact Factor
  • Source
    • "As quoted above, the reported fecal fat excretion of orlistat at 180 mg/d is 25%, yet in a study of 16 weeks’ duration, orlistat at 60 mg TID has been shown to only result in a 3.50 kg weight loss compared with 1.90 kg in the placebo group, with a net weight loss of 1.6 kg.36 In comparison, 2.4 kg mean net body weight loss was observed over a 3-month period during a previous study of cactus fiber,21 suggesting a more pronounced weight loss effect size than explained by the reduced energy intake due to fat excretion alone. The additional weight loss effect may be attributed to other functional properties of fibers contained in cactus fiber; for example, the effects of fibers on promoting satiety37,38 and delaying absorption of nutrients during digestion,32,33,39 which have been frequently reported in literature. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Cactus (Opuntia ficus-indica) fiber was shown to promote weight loss in a 3-month clinical investigation. As demonstrated by in vitro studies, cactus fiber binds to dietary fat and its use results in reduced absorption, which in turn leads to reduced energy absorption and ultimately the reduction of body weight. Objective The objective of our study was to elucidate the dietary fat binding capacity of cactus fiber through determination of fecal fat excretion in healthy volunteers. Subjects and Methods This clinical investigation was performed as a double-blind, randomized, placebo-controlled, crossover study in healthy subjects for a period of approximately 45 days. Twenty healthy volunteer subjects were randomized to receive cactus fiber or placebo, 2 tablets thrice daily with main meals. All subjects were provided with meals during the study period (except washout) according to a standardized meal plan, with 35% of daily energy need coming from fat. Two 24-hour feces samples were collected during both the baseline and treatment periods for analysis of the fat content. Results Cactus fiber showed an increased fecal fat excretion compared with placebo (mean [SD] = 15.79% [5.79%] vs 4.56% [3.09%]; P < 0.001). No adverse events were reported throughout the study period. Conclusions Cactus fiber has been shown to significantly promote fecal fat excretion in healthy adults. The results of our study support the hypothesis that cactus fiber helps in reducing body weight by binding to dietary fat and increasing its excretion, thus reducing dietary fat available for absorption. ClinicalTrials.gov identifier: NCT01590667.
    Current Therapeutic Research 12/2014; 76:39–44. DOI:10.1016/j.curtheres.2014.02.001 · 0.45 Impact Factor
  • Source
    • "There were also no clinical changes observed from blood parameters such as full blood count and clinical chemistry. Furthermore, the intake of Litramine IQP-G-002AS for 12 weeks had not resulted in any clinical relevant changes on the serum fat soluble vitamins (A, D, and E) [28] and serum mineral level (sodium, potassium, magnesium, and calcium) [28, 29]. Nevertheless, studies of more than 24 weeks are needed to examine the long-term safety of Litramine IQP-G-002AS. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sedentary lifestyle and caloric overconsumption are the key determinants of the escalating obesity prevalence. Reducing dietary fat absorption may help to induce a negative energy balance and thus help in managing weight problem. Apart from approved drug therapies, weight problems may also be aided with alternative and natural treatments. This paper compiled and reviewed the efficacy and safety of Litramine IQP-G-002AS, an Opuntia ficus-indica (OFI) derived fiber, in reducing dietary fat absorption and promoting weight loss. Evidence reviewed shows that Litramine IQP-G-002AS displays efficacy in promoting fat excretion and weight loss in four randomized, placebo-controlled clinical studies (including an unpublished pilot study). With a daily dosage of 3 g over a seven-day period, Litramine IQP-G-002AS showed an increased faecal fat excretion compared with placebo (15.8% (SD 5.8%) versus 4.6% (SD 3.1%); P < 0.001). In a 12-week study, significant greater weight loss (3.8 kg (SD 1.8 kg) versus 1.4 kg (SD 2.6 kg); P < 0.001) was observed in overweight and obese subjects treated with Litramine IQP-G-002AS as compared to placebo. No relevant gastrointestinal side effects have been reported for Litramine IQP-G-002AS at the dosages studied.
    Evidence-based Complementary and Alternative Medicine 08/2014; 2014:943713. DOI:10.1155/2014/943713 · 1.88 Impact Factor
Show more